• ClipSaver
ClipSaver
Русские видео
  • Смешные видео
  • Приколы
  • Обзоры
  • Новости
  • Тесты
  • Спорт
  • Любовь
  • Музыка
  • Разное
Сейчас в тренде
  • Фейгин лайф
  • Три кота
  • Самвел адамян
  • А4 ютуб
  • скачать бит
  • гитара с нуля
Иностранные видео
  • Funny Babies
  • Funny Sports
  • Funny Animals
  • Funny Pranks
  • Funny Magic
  • Funny Vines
  • Funny Virals
  • Funny K-Pop

New Era in Anti-Drug Antibody Assays скачать в хорошем качестве

New Era in Anti-Drug Antibody Assays 3 years ago

video

sharing

camera phone

video phone

free

upload

Не удается загрузить Youtube-плеер. Проверьте блокировку Youtube в вашей сети.
Повторяем попытку...
New Era in Anti-Drug Antibody Assays
  • Поделиться ВК
  • Поделиться в ОК
  •  
  •  


Скачать видео с ютуб по ссылке или смотреть без блокировок на сайте: New Era in Anti-Drug Antibody Assays в качестве 4k

У нас вы можете посмотреть бесплатно New Era in Anti-Drug Antibody Assays или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:

  • Информация по загрузке:

Скачать mp3 с ютуба отдельным файлом. Бесплатный рингтон New Era in Anti-Drug Antibody Assays в формате MP3:


Если кнопки скачивания не загрузились НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу страницы.
Спасибо за использование сервиса ClipSaver.ru



New Era in Anti-Drug Antibody Assays

Anti-Drug Antibody (ADA) assays such as ligand-based assays are critical to assess the clinical efficacy and safety of a biological drug. ADA assays rely on control reagents that mimic the ADA response to the biological drug being tested. These positive controls typically consist of animal-derived (e.g., rabbits) pooled polyclonal antibodies (pAb) or human monoclonal antibody (mAb) reference panels against the target protein drug. For timely approval of a protein therapeutic, ADA assays should be developed and validated within 18 months of filing with the FDA. This can be a significant hurdle for many scientists in the industry. Rapid Novor is able to streamline, optimize the process of antibody discovery and minimize cost for anti-drug antibody development. Register for our webinar to find out more about The New Era of Ani-Drug Antibody assays. Current State of Anti-Drug Antibody Assays The former animal-derived standards are prone to many challenges including issues in characterizing which epitope(s) is targeted by the ADA response. Furthermore, due to the finite and variable nature of animal pAb production, new batches still require validation and characterization prior to clinical testing. In contrast, human mAb reference panels can be tedious to generate because they must recapitulate as close as possible the ADA response, which is polyclonal. Solution for the Challenge Recombinant mAbs (rAbs) derived from the anti-drug pAb offer a solution to the aforementioned problems. Using Rapid Novor’s REpAb® Antibody Discovery Platform, pAb sequences can be mined from the naturally occurring patient polyclonal ADA response. Such rAbs would be strictly defined and bear high fidelity. REpAb® could also be used to generate more precise animal-derived pAb ADA positive controls. With REpAb®’s technology, scientists can confidently rely on new and improved ADA positive controls to ease the characterization of ADA responses. You Will Learn How rAb panels derived with proteomics-informed data from anti-drug pAb preparations address current ADA assay shortcomings Learnings from Factor VII ADA responses as a case study Modeling new panels after 2015’s WHO-developed anti-erythropoietin mAb reference panel with ease Review of the role of rAb controls in biosimilar pre-clinical and clinical testing How Polyclonal Antibody Protein Sequencing breakthrough offers a better method to generate rAbs for ADA reference panels Overview of how to gain direct access to the ADA response Review of how REpAb® complements your pipeline efforts Discussion of how the antibody-specific insights provided by our platform can strengthen characterization studies. Speaker Anthony Stajduhar Director of International Business Development at Rapid NovorAnthony Stajduhar, B.Eng. Director of International Business Development at Rapid Novor Anthony works with leading researchers in antibody discovery and diagnostic development to understand their needs and ensure that REpAp® polyclonal antibody sequencing technology complements existing approaches and/or provides a complete end-to-end solution. Anthony is dedicated to solving challenging technical problems in the biomedical field, while enriching the lives of humans around the world.

Comments
  • Latest Advancements in Antibody Engineering – Bispecifics, Diagnostic Controls, and More 1 year ago
    Latest Advancements in Antibody Engineering – Bispecifics, Diagnostic Controls, and More
    Опубликовано: 1 year ago
    2213
  • Understanding CRISPR-Cas9 3 years ago
    Understanding CRISPR-Cas9
    Опубликовано: 3 years ago
    239489
  • Introduction to the immune system 1 year ago
    Introduction to the immune system
    Опубликовано: 1 year ago
    306772
  • Types of IV Fluid - Fluid Management 4 years ago
    Types of IV Fluid - Fluid Management
    Опубликовано: 4 years ago
    1963110
  • Climate Change Collaboration | The Agenda 7 years ago
    Climate Change Collaboration | The Agenda
    Опубликовано: 7 years ago
    1442
  • 4 days ago
    "Empire of AI": Karen Hao on How AI Is Threatening Democracy & Creating a New Colonial World
    Опубликовано: 4 days ago
    201669
  • Nicole Yunger Halpern - Quantum steampunk: Quantum information meets thermodynamics 6 years ago
    Nicole Yunger Halpern - Quantum steampunk: Quantum information meets thermodynamics
    Опубликовано: 6 years ago
    1682
  • Rational Antibody Design and Engineering with Next Generation Protein Sequencing 1 year ago
    Rational Antibody Design and Engineering with Next Generation Protein Sequencing
    Опубликовано: 1 year ago
    4186
  • CRISPR-Cas9 Genome Editing Technology 3 years ago
    CRISPR-Cas9 Genome Editing Technology
    Опубликовано: 3 years ago
    807566
  • Introduction to pharmacology 1 year ago
    Introduction to pharmacology
    Опубликовано: 1 year ago
    252660

Контактный email для правообладателей: [email protected] © 2017 - 2025

Отказ от ответственности - Disclaimer Правообладателям - DMCA Условия использования сайта - TOS



Карта сайта 1 Карта сайта 2 Карта сайта 3 Карта сайта 4 Карта сайта 5